PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1536.00 - 1565.00
1090.00 - 1784.00
46.2K / 155.6K (Avg.)
23.48 | 66.41
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-27.40%
Both firms have declining sales. Martin Whitman would suspect an industry slump or new disruptive entrants.
-30.39%
Negative gross profit growth while 6247.T is at 1.07%. Joel Greenblatt would examine cost competitiveness or demand decline.
-146.88%
Negative EBIT growth while 6247.T is at 111.80%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-162.90%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-180.00%
Negative net income growth while 6247.T stands at 111.28%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-180.00%
Negative EPS growth while 6247.T is at 111.31%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-180.00%
Negative diluted EPS growth while 6247.T is at 111.31%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
9.59%
OCF growth at 50-75% of 6247.T's 17.03%. Martin Whitman would question if the firm lags in monetizing sales effectively.
9.59%
FCF growth 50-75% of 6247.T's 17.03%. Martin Whitman would see if structural disadvantages exist in generating free cash.
-30.52%
Negative 10Y revenue/share CAGR while 6247.T stands at 55.21%. Joel Greenblatt would question if the company is failing to keep pace with industry changes.
-6.70%
Negative 5Y CAGR while 6247.T stands at 5.52%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
1.86%
3Y revenue/share CAGR under 50% of 6247.T's 13.22%. Michael Burry might see a serious short-term decline in relevance vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-147.74%
Negative 10Y net income/share CAGR while 6247.T is at 542.62%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-1678.92%
Negative 5Y net income/share CAGR while 6247.T is 157.71%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
-56.19%
Negative 3Y CAGR while 6247.T is 129.49%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
101.72%
10Y equity/share CAGR above 1.5x 6247.T's 37.27%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
48.01%
5Y equity/share CAGR above 1.5x 6247.T's 20.16%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
31.40%
3Y equity/share CAGR above 1.5x 6247.T's 10.09%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
12.82%
Our AR growth while 6247.T is cutting. John Neff questions if the competitor outperforms in collections or if we’re pushing credit to maintain sales.
19.48%
Inventory growth well above 6247.T's 14.21%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
13.51%
Asset growth above 1.5x 6247.T's 1.36%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
-0.62%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
32.76%
Debt growth far above 6247.T's 11.83%. Michael Burry fears the firm is taking on undue leverage vs. the competitor.
42.86%
R&D growth drastically higher vs. 6247.T's 27.27%. Michael Burry fears near-term margin erosion unless breakthroughs are imminent.
-0.46%
We cut SG&A while 6247.T invests at 11.17%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.